RNAs As Candidate Diagnostic and Prognostic Markers of Prostate Cancer-From Cell Line Models to Liquid Biopsies

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2018 Sep 12

PMID 30200254

Citations 13

Authors

Marvin C J Lim

Anne-Marie Baird

John Aird

John Greene

Dhruv Kapoor

Steven G Gray

Ray McDermott

Stephen P Finn

Affiliations

Soon will be listed here.

Abstract

The treatment landscape of prostate cancer has evolved rapidly over the past five years. The explosion in treatment advances has been witnessed in parallel with significant progress in the field of molecular biomarkers. The advent of next-generation sequencing has enabled the molecular profiling of the genomic and transcriptomic architecture of prostate and other cancers. Coupled with this, is a renewed interest in the role of non-coding RNA (ncRNA) in prostate cancer biology. ncRNA consists of several different classes including small non-coding RNA (sncRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA). These families are under active investigation, given their essential roles in cancer initiation, development and progression. This review focuses on the evidence for the role of RNAs in prostate cancer, and their use as diagnostic and prognostic markers, and targets for treatment in this disease.

Citing Articles

Transcript Markers from Urinary Extracellular Vesicles for Predicting Risk Reclassification of Prostate Cancer Patients on Active Surveillance.

Erdmann K, Distler F, Grafe S, Kwe J, Erb H, Fuessel S Cancers (Basel). 2024; 16(13).

PMID: 39001515 PMC: 11240337. DOI: 10.3390/cancers16132453.

Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer.

Mao Y, Yang G, Li Y, Liang G, Xu W, Hu M Cancers (Basel). 2022; 14(15).

PMID: 35954408 PMC: 9367587. DOI: 10.3390/cancers14153744.

The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.

Hu C, Wu K, Lin T, Chen C Int J Mol Sci. 2022; 23(1).

PMID: 35008817 PMC: 8745162. DOI: 10.3390/ijms23010392.

Circ_0044516 Enriches the Level of SARM1 as a miR-330-5p Sponge to Regulate Cell Malignant Behaviors and Tumorigenesis of Prostate Cancer.

Wu Y Biochem Genet. 2022; 60(4):1346-1361.

PMID: 34993722 DOI: 10.1007/s10528-021-10160-w.

Circular RNAs in prostate cancer: Biogenesis,biological functions, and clinical significance.

Liu X, Tong Y, Xia D, Peng E, Yang X, Liu H Mol Ther Nucleic Acids. 2021; 26:1130-1147.

PMID: 34820150 PMC: 8585584. DOI: 10.1016/j.omtn.2021.10.017.

References

Hugosson J, Carlsson S . Overdetection in screening for prostate cancer. Curr Opin Urol. 2014; 24(3):256-63. DOI: 10.1097/MOU.0000000000000054. View

Kattan M, Wheeler T, Scardino P . Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17(5):1499-507. DOI: 10.1200/JCO.1999.17.5.1499. View

Borque A, Rubio-Briones J, Esteban L, Sanz G, Dominguez-Escrig J, Ramirez-Backhaus M . Implementing the use of nomograms by choosing threshold points in predictive models: 2012 updated Partin Tables vs a European predictive nomogram for organ-confined disease in prostate cancer. BJU Int. 2014; 113(6):878-86. DOI: 10.1111/bju.12532. View

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

Brameier M, Herwig A, Reinhardt R, Walter L, Gruber J . Human box C/D snoRNAs with miRNA like functions: expanding the range of regulatory RNAs. Nucleic Acids Res. 2010; 39(2):675-86. PMC: 3025573. DOI: 10.1093/nar/gkq776. View

Leyten G, Hessels D, Jannink S, Smit F, de Jong H, Cornel E . Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2012; 65(3):534-42. DOI: 10.1016/j.eururo.2012.11.014. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Jansson M, Lund A . MicroRNA and cancer. Mol Oncol. 2012; 6(6):590-610. PMC: 5528350. DOI: 10.1016/j.molonc.2012.09.006. View

10.

Bussemakers M, van Bokhoven A, Verhaegh G, Smit F, Karthaus H, Schalken J . DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23):5975-9. View

11.

Dudekula D, Panda A, Grammatikakis I, De S, Abdelmohsen K, Gorospe M . CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 2015; 13(1):34-42. PMC: 4829301. DOI: 10.1080/15476286.2015.1128065. View

12.

Zeng K, Chen X, Xu M, Liu X, Hu X, Xu T . CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7. Cell Death Dis. 2018; 9(4):417. PMC: 5856798. DOI: 10.1038/s41419-018-0454-8. View

13.

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

14.

Ambs S, Prueitt R, Yi M, Hudson R, Howe T, Petrocca F . Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008; 68(15):6162-70. PMC: 2597340. DOI: 10.1158/0008-5472.CAN-08-0144. View

15.

He J, Li B, Han Z, Zou M, Wang L, Lv Y . Snail-activated long non-coding RNA PCA3 up-regulates PRKD3 expression by miR-1261 sponging, thereby promotes invasion and migration of prostate cancer cells. Tumour Biol. 2016; 37:16163–16176. DOI: 10.1007/s13277-016-5450-y. View

16.

Olvedy M, Scaravilli M, Hoogstrate Y, Visakorpi T, Jenster G, Martens-Uzunova E . A comprehensive repertoire of tRNA-derived fragments in prostate cancer. Oncotarget. 2016; 7(17):24766-77. PMC: 5029740. DOI: 10.18632/oncotarget.8293. View

17.

Lee Y, Jeon K, Lee J, Kim S, Kim V . MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 2002; 21(17):4663-70. PMC: 126204. DOI: 10.1093/emboj/cdf476. View

18.

Glazar P, Papavasileiou P, Rajewsky N . circBase: a database for circular RNAs. RNA. 2014; 20(11):1666-70. PMC: 4201819. DOI: 10.1261/rna.043687.113. View

19.

Na X, Liu Z, Ren P, Yu R, Shang X . Long non-coding RNA UCA1 contributes to the progression of prostate cancer and regulates proliferation through KLF4-KRT6/13 signaling pathway. Int J Clin Exp Med. 2015; 8(8):12609-16. PMC: 4612857. View

20.

Larne O, Martens-Uzunova E, Hagman Z, Edsjo A, Lippolis G, den Berg M . miQ--a novel microRNA based diagnostic and prognostic tool for prostate cancer. Int J Cancer. 2012; 132(12):2867-75. DOI: 10.1002/ijc.27973. View